Taking Wing With Biotech Angel Investors
This article was originally published in Start Up
They’re not just for seed rounds anymore: in the life sciences, rich individuals are supplying more early stage capital than ever, occasionally well past the Series A stage, and some are banding together into groups that look increasingly like traditional venture capital. How far will this phenomenon fly?
You may also be interested in...
The Massachusetts biotech has remained well-funded despite shying away from venture capital investors and seeking funds from private investors.